← Leaderboards
Scott A Barman
Augusta University
$6,157,524
Attributed
$9,991,665
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,991,665 · 3
By mechanism
R01$9,991,665 · 3
Top collaborators
- David J Fulton12 shared
Most similar at Augusta University
Same institution · by research overlap
- David J Fulton$11,867,025
- Olga Rafikova$5,082,063
- Tohru Fukai$10,473,455
- Neal L Weintraub$17,807,491
- Laszlo Kovacs$760,760
Others in their field
Top investigators on “Signal Pathway”
- David Heimbrook · Leidos Biomedical Research, Inc.$191,912,844
- Asrar B. Malik · University Of Illinois At Chicago$75,811,832
- Robert H Tukey · University Of California San Diego$50,504,865
- Meenhard Herlyn · University Of Pennsylvania$50,308,097
- Ian A Wilson · Scripps Research Institute, The$50,300,809
- Richard D Smith · Battelle Pacific Northwest Laboratories$46,192,560
Research focus
Signal PathwayRattusDiagnosisLungCellsPulmonary Arterial HypertensionPulmonary Artery StructureSmooth Muscle MyocytesAnimal ModelMediatingPathologicMorbidity - Disease RateKnock-OutBindingPathogenesisPhenotypeMedialBlood VesselsIndexingIn VitroDigitalCharacteristicsCell ProliferationGenes
Grant awards (20)
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2025 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$686,685
R01 · FY2024 · HL
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$671,594
R01 · FY2024 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2023 · HL
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2023 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$700,700
R01 · FY2022 · HL
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2022 · HL
PBK: A novel mediator of VSMC proliferation and vascular remodeling in PAH$685,300
R01 · FY2021 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2019 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2018 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2017 · HL
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension$538,001
R01 · FY2016 · HL
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$330,750
R01 · FY2010 · HL · contact PI
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$330,750
R01 · FY2009 · HL · contact PI
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$330,750
R01 · FY2008 · HL · contact PI
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$330,469
R01 · FY2007 · HL · contact PI
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$251,125
R01 · FY2004 · HL
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$251,125
R01 · FY2003 · HL
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$251,125
R01 · FY2002 · HL
PKC Signaling in cAMP-Induced Pulmonary Vasodilation$247,288
R01 · FY2001 · HL